← feed

Is NCT02497716 results overdue?

Yes — results are overdue. Primary completion was 2018-05-22; the FDAAA-801 reporting deadline (2019-05-22) passed 2633 days ago and no results are posted on ClinicalTrials.gov.

Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children

NCT IDNCT02497716 ↗
SponsorBayer (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2018-05-22 (ACTUAL)
Reporting deadline2019-05-22 (completion + 365d)
Days overdue2633
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 e95606dc0d5eec6d… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02497716. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →